Nutriband logo
Nutriband
NTRB | NASDAQ
Chart Builder DCF Calculator
$5.81
-$0.29 (-4.75%)
At close: Nov 16, 2026, 4:00 PM ET
$6.00
+$0.19 (+3.27%)
After-hours: Nov 16, 2026, 7:30 PM ET

Nutriband Company Profile

Company profile explained

Company Profile

Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.

Key Executives

Name Position
Gareth Sheridan Founder, Chief Executive Officer & Director
Alan Smith Chief Operating Officer & President of 4P Therapeutics
Gerald Goodman Chief Financial Officer & Chief Accounting Officer
Jeffrey Patrick Chief Scientific Officer
Michael Myer President of Pocono Pharmaceutical
Serguei Melnik Founder, President, Company Secretary & Executive Chairman
Tyler Overk Head of Active Intelligence

Latest SEC Filings

Date Type Title
Sep 30, 2026 25-NSE Filing
Sep 23, 2026 8-K Current Report
Sep 15, 2026 SC 13D/A [Amend] Filing
Sep 04, 2026 10-Q Quarterly Report
Jun 22, 2026 8-K Current Report
Jun 11, 2026 10-Q Quarterly Report
May 18, 2026 10-K/A [Amend] Annual Report
Apr 29, 2026 10-K Annual Report
Apr 07, 2026 8-K Current Report
Feb 13, 2026 8-K Current Report
View All SEC Filings ➞
Nutriband
Nutriband logo
Country United States
IPO Date Oct 1, 2021
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Gareth Sheridan

Contact Details

121 South Orange Avenue Orlando, Florida 32801 United States

Stock Details

Ticker Symbol NTRB
Exchange NASDAQ
Fiscal Year February - January
Reporting Currency USD
CIK Code 0001676047
CUSIP Number 67092M208
ISIN Number US67092M2089
SIC Code 3842

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.